Semintra Oral Solution is an oral solution that has been specifically designed for cats to reduce the amount of protein lost in their urine. Used for deduction of proteinuria associated with chronic kidney disease in cats. Losing too much protein in the urine is associated with a shorter life expectancy in cats suffering from chronic kidney disease.
Semintra is indicated for the control of systemic hypertension in cats.
Always provide the Client Information Sheet with each prescription. The initial dose of Semintra is 1.5 mg/kg (0.68 mg/lb) orally twice daily for 14 days, followed by 2 mg/kg (0.91 mg/lb) orally once daily. The dose may reduced by 0.5 mg/kg (0.23 mg/lb) increments to a minimum of 0.5 mg/kg (0.23 mg/lb) orally once daily to manage Semintra-induce hypotension. Semintra can be administered directly into the mouth, or next to or on top of a small amount of food. Do not mix into food.
Semintra should be administered using the dosing syringe provided in the package. The dosing syringe fits onto the bottle and has 0.1 mL incremental marks. The dose should be rounded to the nearest 0.1 mL. After the administration closes the bottle tightly with the cap. Rinse the dosing syringe with water and let air dry.
If the cat vomits within 30 minutes of dosing, the cat may be re-dosed.
Store at or below 25°C (77°F) with excursions permitted up to 40°C (104°F). Once the bottle is opened, use the contents within six months. Keep away from children and pets.
Do not use in cats with a known hypersensitivity to telmisartan.
If your cat vomits within 30 minutes of giving the Semintra (telmisartan oral solution) dose, your cat can be given the same dose again. If your cat vomits more than 30 minutes after giving Semintra, do not give Semintra again until the next scheduled dose.
After dosing, replace the cap on the bottle and close tightly, Rinse the Semintra dosing syringe with water and let air dry.
Semintra is not for use in humans.
You should keep Semintra in a secure storage area out of the reach of children.
Pregnant women should avoid contact with Semintra because other similar drugs have been found to harm the unborn baby during pregnancy.
If Semintra is accidentally ingested, contact a physician, It is important to show the treating physician a copy of the package insert, label, or client information sheet. Semintra is an angiotensin II receptor blocker.
Semintra has not been evaluated in cats with systolic blood pressure >200 mm Hg.
Semintra can cause mild anemia or non-regenerative anemia. Cats should be monitored for anemia when initiating treatment with Semintra.
Semintra may cause inappetence and weight loss in some cats. Cats should be monitored for weight loss when initiating treatment with Semintra. Use with caution in cats with a history of vomiting, inappetence or weight loss.
The safe use of Semintra in cats with hepatic disease has not been evaluated. Semintra is metabolized by the liver.
The safe use of Semintra has not been evaluated in cats less than 9 months of age.
The safe use of Semintra has not been evaluated in cats that are pregnant, lactating, or intended for breeding.
The safe use with other anti-hypertensive medications has not been evaluated.
Like all drugs, Semintra may cause side effects, even at the prescribed dose. Serious side effects can occur, with or without warning, and in some situation result in death. Contact your veterinarian immediately if your cat develops a medical problem or side effect while taking Semintra.
The most common side effects which can occur with Semintra include vomiting, diarrhea, lethargy, weight loss, anemia (low red blood cell count) and dehydration.
There are other side effects which may occur. For a complete list, ask your veterinarian.
Talk to you veterinarian about: